PubMed:2153347 JSONTXT

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":242,"end":259},"obj":"HP_0003002"},{"id":"T2","span":{"begin":336,"end":342},"obj":"HP_0002664"},{"id":"T3","span":{"begin":417,"end":422},"obj":"HP_0002664"},{"id":"T4","span":{"begin":450,"end":467},"obj":"HP_0003002"},{"id":"T5","span":{"begin":574,"end":580},"obj":"HP_0002664"},{"id":"T6","span":{"begin":766,"end":772},"obj":"HP_0002664"},{"id":"T7","span":{"begin":843,"end":849},"obj":"HP_0002664"},{"id":"T8","span":{"begin":896,"end":901},"obj":"HP_0002664"},{"id":"T9","span":{"begin":1037,"end":1054},"obj":"HP_0003002"}],"text":"Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction.\nVimentin expression, growth fractions (GF), and estrogen receptor (ER) levels were determined for 90 untreated primary breast carcinomas. Coexpression of keratin and vimentin was found in approximately 20% of the tumors regardless of menopausal status. Vimentin was expressed preferentially in tumor cells of high-grade ductal breast carcinomas (15 of 28 histologic grade 3 vs. 0 of 40 grades 1 and 2). Vimentin expression was found preferentially in tumors with high GF (greater than 15% Ki-67 positive by immunoperoxidase staining) and low ER levels (less than 60 fmols/mg protein by a monoclonal enzyme immunoassay). Sixty-eight percent of tumors in this group were vimentin positive and 88% of all vimentin-positive tumors fell into this category. More than 50% of the tumor cells coexpressed vimentin and keratin. Thus, vimentin expression may be helpful in identifying a substantial subset of ER-independent breast carcinomas with poor prognostic indicators."}

{"project":"bionlp-st-cg-2013-training","denotations":[{"id":"T1","span":{"begin":0,"end":8},"obj":"Gene_or_gene_product"},{"id":"T2","span":{"begin":40,"end":45},"obj":"Organism"},{"id":"T3","span":{"begin":46,"end":63},"obj":"Cancer"},{"id":"T4","span":{"begin":73,"end":90},"obj":"Gene_or_gene_product"},{"id":"T5","span":{"begin":100,"end":105},"obj":"Gene_or_gene_product"},{"id":"T6","span":{"begin":123,"end":131},"obj":"Gene_or_gene_product"},{"id":"T7","span":{"begin":171,"end":188},"obj":"Gene_or_gene_product"},{"id":"T8","span":{"begin":190,"end":192},"obj":"Gene_or_gene_product"},{"id":"T9","span":{"begin":242,"end":259},"obj":"Cancer"},{"id":"T10","span":{"begin":277,"end":284},"obj":"Gene_or_gene_product"},{"id":"T11","span":{"begin":289,"end":297},"obj":"Gene_or_gene_product"},{"id":"T12","span":{"begin":336,"end":342},"obj":"Cancer"},{"id":"T13","span":{"begin":376,"end":384},"obj":"Gene_or_gene_product"},{"id":"T14","span":{"begin":417,"end":428},"obj":"Cell"},{"id":"T15","span":{"begin":432,"end":467},"obj":"Cancer"},{"id":"T16","span":{"begin":526,"end":534},"obj":"Gene_or_gene_product"},{"id":"T17","span":{"begin":574,"end":580},"obj":"Cancer"},{"id":"T18","span":{"begin":612,"end":617},"obj":"Gene_or_gene_product"},{"id":"T19","span":{"begin":630,"end":646},"obj":"Gene_or_gene_product"},{"id":"T20","span":{"begin":665,"end":667},"obj":"Gene_or_gene_product"},{"id":"T21","span":{"begin":766,"end":772},"obj":"Cancer"},{"id":"T22","span":{"begin":792,"end":800},"obj":"Gene_or_gene_product"},{"id":"T23","span":{"begin":825,"end":833},"obj":"Gene_or_gene_product"},{"id":"T24","span":{"begin":843,"end":849},"obj":"Cancer"},{"id":"T25","span":{"begin":896,"end":907},"obj":"Cell"},{"id":"T26","span":{"begin":920,"end":928},"obj":"Gene_or_gene_product"},{"id":"T27","span":{"begin":933,"end":940},"obj":"Gene_or_gene_product"},{"id":"T28","span":{"begin":948,"end":956},"obj":"Gene_or_gene_product"},{"id":"T29","span":{"begin":1022,"end":1024},"obj":"Gene_or_gene_product"},{"id":"T30","span":{"begin":1037,"end":1054},"obj":"Cancer"}],"text":"Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction.\nVimentin expression, growth fractions (GF), and estrogen receptor (ER) levels were determined for 90 untreated primary breast carcinomas. Coexpression of keratin and vimentin was found in approximately 20% of the tumors regardless of menopausal status. Vimentin was expressed preferentially in tumor cells of high-grade ductal breast carcinomas (15 of 28 histologic grade 3 vs. 0 of 40 grades 1 and 2). Vimentin expression was found preferentially in tumors with high GF (greater than 15% Ki-67 positive by immunoperoxidase staining) and low ER levels (less than 60 fmols/mg protein by a monoclonal enzyme immunoassay). Sixty-eight percent of tumors in this group were vimentin positive and 88% of all vimentin-positive tumors fell into this category. More than 50% of the tumor cells coexpressed vimentin and keratin. Thus, vimentin expression may be helpful in identifying a substantial subset of ER-independent breast carcinomas with poor prognostic indicators."}